Summary
The absorption of digoxin from two capsule preparations containing a large number of small, enteric-coated granules of the glycoside (0.38 mg) was compared with that of the same amount from ultrarapidly dissolving commercial tablets. Eight volunteers were studied during steady state conditions. Digoxin concentrations in plasma and urine were measured by radioimmunoassay. Peak plasma concentrations of digoxin were significantly (p<0.01) delayed after taking the capsules (2.6±1 h and 2.6±0.9 h, mean±SD) as compared to the tablets (1.3±0.7 h). The peak concentrations produced by the capsules were 3.1±1.0 and 2.6±1.1 nmol/l; only the latter was significantly (p<0.05) lower than after the tablets (3.4±1.0 nmol/l). Areas under the plasma concentration-time curves during a 24 h dosage interval were similar for the three preparations, and so was the 24 h urinary excretion of digoxin, which averaged 60–63% of the daily dose. Thus, this particular enteric coating of digoxin delayed absorption without reducing the amount absorbed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alpsten M, Bogentoft C, Ekenved G, Sölvell L (1979) On the disintegration of hard gelatine capsules in fasting volunteers using a profile scanning technique. J Pharm Pharmacol 31: 480–481
Alpsten M, Bogentoft C, Ekenved G, Sölvell L (1980) Gastric emptying and absorption of acetylsalicylic acid administered as enteric-coated microgranules. (Submitted to publication)
Bergdahl B, Molin L, Lindvall L, Dahlström G, Scherling I, Bertler Å (1979) Four kits for plasma digoxin radioimmunoassay compared. Clin Chem 25: 305–308
Bertler Å, Medin S, Nyberg L, Redfors A (1972) Bioavailability of digoxin. Lancet 2: 708
Bogentoft C, Carlsson I, Ekenved E, Magnusson A (1978) Influence of food on the absorption of acetylsalicylic acid from enteric coated dosage forms. Eur J Clin Pharmacol 14: 351–355
Castle MC (1975) Isolation and quantitation of picomole quantities of digoxin, digitoxin and their metabolites by high-pressure liquid chromatography. J Chromatogr 115: 437–445
Clark RL, Lasagna L (1965) How reliable are enteric coated aspirin preparations? Clin Pharmacol Ther 6: 568–574
Dobbs SM, Rodgers EM, Kenyon WI, Livshin D, Slater E, Godsmark B (1977) Digoxin prescribing in perspective. Br J Clin Pharmacol 4: 327–335
Flasch H, Asmussen B, Heinz N (1978) Erhöhte Bioverfügbarkeit von Digoxin aus Kieselsäure Matrix Zubereitungen. Arzneim Forsch 28: 326–330
Gault MH, Charles JD, Sugden DL, Kepkay DC (1977) Hydrolysis of digoxin by acid. J Pharm Pharmacol 29: 27–32
Greenblatt DJ, Smith TW, Koch-Weser J (1976) Bioavailability of drugs: The digoxin dilemma. Clin Pharmacokinet 1: 36–51
Harter JG, Skelly JP, Steers AW (1974) Digoxin — the regulatory view point. Circulation 49: 395–398
Hendersson RG, Wheatley T, English J, Chakraborty J, Marks V (1979) Variation in plasma prednisolone concentrations in renal transplant recipients given enteric-coated prednisolone. Br Med J 1: 1534–1536
Hulme B, James VHT, Rault R (1975) Absorption of enteric and non-enteric coated prednisolone tablets. Br J Clin Pharmacol 2: 317–320
Iisalo E, Ruikka I (1974) Serum levels and renal excretion of digoxin in the elderly. A comparison between three different preparations. Acta Med Scand 196: 59–63
Johnson BF, Bye CE, Jones GE, Sabey GA (1976) The pharmacokinetics of beta-methyl digoxin compared with digoxin tablet and capsules. Eur J Clin Pharmacol 10: 231–236
Kuhlmann J, Abshagen U, Rietbrock N (1973) Cleavage of glycosidic bonds of digoxin and derivates as function of pH and time. Naunyn Schmiedeberg's Arch Pharmacol 276: 149–156
Mallis GI, Schmidt DH, Lindenbaum J (1975) Superior bioavailability of digoxin solution in capsules. Clin Pharmacol Ther 18: 761–768
Manninen V, Reissell P, Pankkala E (1976) Transient cardiac arrhythmias after single daily maintenance doses of digoxin. Clin Pharmacol Ther 20: 266–268
Marcus FI, Quinn EJ, Horton H, Jacobs S, Pippin S, Stafford M, Zuboski C (1977) The effect of jejunoileal bypass on the pharmacokinetics of digoxin in man. Circulation 3: 537–541
Nyberg L (1977) Bioavailability of digoxin in man after oral administration of preparations with different dissolution rate. Acta Pharmacol Toxicol 40, III: 26–28
Nyberg L, Bratt L, Forsgren A, Hugosson S (1974A) Bioavailability of digoxin from tablets. I. In vitro characterization of digoxin tablets. Acta Pharm Suec 11: 447–458
Nyberg L, Andersson KE, Bertler Å (1974B) Bioavailability of digoxin from tablets. III. Availability of digoxin in man from preparations with different dissolution rate. Acta Pharm Suec 11: 471–492
Nyberg L, Andersson KE, Fagerström PO (1977) Bioavailability of digoxin from tablets. IV. Urinary excretion of digoxin during multiple dose treatment. Acta Pharm Suec 14: 119–136
Redfors A (1972) Plasma digoxin concentration — its relation to digoxin dosage and clinical effects in patients with atrial fibrillation. Br Heart J 34: 383–391
Shaw TRD, Howard MR, Hamer J (1974) Influence of formulation on absorption and clinical effect of digoxin. Br Heart J 36: 400
Smith TW (1975) Digitalis toxicity: Epidemiology and clinical use of serum concentration measurements. Am J. Med 58: 470–476
Sternson LA, Shaffer RD (1978) Kinetics of digoxin stability in aqueous solution. J Pharm Sci 67: 327–330
Wagner JG, Stoll RG, Wiedler JD, Ayres JW, Hallmark MR, Sakmar E, Yacobi A (1979) Comparison of the in vitro and in vivo release of digoxin from four different soft gelatine capsule formulations. J Pharmacokinet Biopharm 7: 147–158
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bergdahl, B., Bogentoft, C., Jonsson, U.E. et al. Absorption of digoxin from a new microencapsulated formulation. Eur J Clin Pharmacol 17, 443–447 (1980). https://doi.org/10.1007/BF00570162
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00570162